vs
Side-by-side financial comparison of Ellington Financial Inc. (EFC) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
Ellington Financial Inc. is the larger business by last-quarter revenue ($78.2M vs $60.1M, roughly 1.3× RHYTHM PHARMACEUTICALS, INC.). Ellington Financial Inc. runs the higher net margin — 28.9% vs -92.6%, a 121.5% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (83.8% vs 8.7%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (43.8% CAGR vs 1.8%).
Ellington Management Group is an American hedge fund firm. As of June 2019, the firm was reportedly managing $8.5 billion in structured products and other credit instruments.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
EFC vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $78.2M | $60.1M |
| Net Profit | $22.6M | $-55.6M |
| Gross Margin | — | 88.1% |
| Operating Margin | 7.4% | -87.1% |
| Net Margin | 28.9% | -92.6% |
| Revenue YoY | 8.7% | 83.8% |
| Net Profit YoY | -26.2% | — |
| EPS (diluted) | $0.10 | $-0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $60.1M | ||
| Q4 25 | $78.2M | $57.3M | ||
| Q3 25 | $82.8M | $51.3M | ||
| Q2 25 | $92.5M | $48.5M | ||
| Q1 25 | $82.9M | $32.7M | ||
| Q4 24 | $72.0M | $41.8M | ||
| Q3 24 | $67.0M | $33.3M | ||
| Q2 24 | $91.2M | $29.1M |
| Q1 26 | — | $-55.6M | ||
| Q4 25 | $22.6M | $-47.5M | ||
| Q3 25 | $29.5M | $-52.9M | ||
| Q2 25 | $42.9M | $-46.6M | ||
| Q1 25 | $31.6M | $-49.5M | ||
| Q4 24 | $30.7M | $-43.3M | ||
| Q3 24 | $16.2M | $-43.6M | ||
| Q2 24 | $52.3M | $-32.3M |
| Q1 26 | — | 88.1% | ||
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% |
| Q1 26 | — | -87.1% | ||
| Q4 25 | 7.4% | -82.2% | ||
| Q3 25 | 31.1% | -102.6% | ||
| Q2 25 | 38.3% | -93.4% | ||
| Q1 25 | 37.3% | -143.7% | ||
| Q4 24 | 28.0% | -98.6% | ||
| Q3 24 | 24.0% | -132.0% | ||
| Q2 24 | 52.8% | -139.2% |
| Q1 26 | — | -92.6% | ||
| Q4 25 | 28.9% | -83.0% | ||
| Q3 25 | 35.7% | -103.1% | ||
| Q2 25 | 46.4% | -96.1% | ||
| Q1 25 | 38.2% | -151.4% | ||
| Q4 24 | 42.6% | -103.6% | ||
| Q3 24 | 24.1% | -131.2% | ||
| Q2 24 | 57.4% | -110.9% |
| Q1 26 | — | $-0.83 | ||
| Q4 25 | $0.10 | $-0.73 | ||
| Q3 25 | $0.29 | $-0.82 | ||
| Q2 25 | $0.45 | $-0.75 | ||
| Q1 25 | $0.35 | $-0.81 | ||
| Q4 24 | $0.23 | $-0.71 | ||
| Q3 24 | $0.19 | $-0.73 | ||
| Q2 24 | $0.62 | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $201.9M | $340.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.8B | $122.9M |
| Total Assets | $19.4B | $442.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $340.6M | ||
| Q4 25 | $201.9M | $388.9M | ||
| Q3 25 | $184.8M | $416.1M | ||
| Q2 25 | $211.0M | $291.0M | ||
| Q1 25 | $203.3M | $314.5M | ||
| Q4 24 | $192.4M | $320.6M | ||
| Q3 24 | $217.7M | $298.4M | ||
| Q2 24 | $198.5M | $319.1M |
| Q1 26 | — | $122.9M | ||
| Q4 25 | $1.8B | $139.1M | ||
| Q3 25 | $1.8B | $148.8M | ||
| Q2 25 | $1.7B | $-11.9M | ||
| Q1 25 | $1.6B | $18.9M | ||
| Q4 24 | $1.6B | $21.7M | ||
| Q3 24 | $1.6B | $11.2M | ||
| Q2 24 | $1.6B | $39.3M |
| Q1 26 | — | $442.3M | ||
| Q4 25 | $19.4B | $480.2M | ||
| Q3 25 | $17.8B | $506.9M | ||
| Q2 25 | $17.1B | $372.7M | ||
| Q1 25 | $16.6B | $386.7M | ||
| Q4 24 | $16.3B | $392.3M | ||
| Q3 24 | $16.0B | $363.6M | ||
| Q2 24 | $15.1B | $381.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-925.5M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | -40.92× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-925.5M | $-25.4M | ||
| Q3 25 | $-290.4M | $-26.6M | ||
| Q2 25 | $-210.5M | $-23.3M | ||
| Q1 25 | $-126.4M | $-40.4M | ||
| Q4 24 | $-430.5M | $-18.8M | ||
| Q3 24 | $-141.7M | $-25.2M | ||
| Q2 24 | $-88.6M | $-29.1M |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | -40.92× | — | ||
| Q3 25 | -9.84× | — | ||
| Q2 25 | -4.90× | — | ||
| Q1 25 | -3.99× | — | ||
| Q4 24 | -14.04× | — | ||
| Q3 24 | -8.76× | — | ||
| Q2 24 | -1.69× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
